NCT04392960Completed
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Molecular, Magnetic Resonance, and Echocardiographic Imaging Combined With Biomarkers of Cardiac and Clonal Disease to Predict Survival and Assess Response to Therapy in Cardiac AL Amyloidosis
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 27 Feb 2020
- Start date
- 22 Jul 2020
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Amyloidosis
- NCT number
- NCT04392960
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 22 Jul 2020 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- severe allergy to paramagnetic tracer;
Other
- non-AL amyloidosis;
- NYHA class IV;
- PS-ECOG \>3;
- severe claustrophobia;
- pregnant or nursing women;
Who the study is looking for
- age more than 18;
- histological diagnosis of AL amyloidosis;
- measurable cardiac involvement as per current response criteria (i.e. NT-proBNP \>650 ng/L);
- measurable hematologic disease (dFLC \>20 mg/L);
- adequate renal function (eGFR \>30 mL/min) in order to be safely administered gadolinium;
- absence of atrial fibrillation with uncontrolled heart rate;
- absence of implantable cardiac devices;
- absence of pulmonary amyloidosis histologically documented;
- plan to start anti-plasma cell chemotherapy;
- plan to assess response at the Pavia center after 6 months;
- have given written informed consent to participate.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.